Skip to main content

White paper

Clinicogenomics: Linked data advances research

Since the human genome was first sequenced life sciences researchers have sought to use this information to improve health. But they soon discovered that DNA sequence data alone has limited value when trying to understand the effects of genetic variation on health.

Today, researchers are increasingly linking genomic data to rich, longitudinal clinical information — a practice that yields clinicogenomics data. The field of clinicogenomics is unlocking novel insights to better understand diseases and to guide drug discovery, development and commercialization.

The study of clinicogenomics across large, diverse populations can help researchers:

  • Better understand disease pathways
  • Discover novel therapeutic targets
  • Identify variation in disease onset and progression
  • Evaluate drug safety and efficacy

Our latest white paper details the foundations of genomics-driven research and the sources of clinicogenomics data. It also highlights the ways clinicogenomics data can enhance clinical trials and fuel discovery and development of safer, more effective drugs.

Related healthcare insights

Article

Patient access to gene therapies for rare disorders

Optum Life Sciences experts discuss value-based contracts at the 5th Annual Gene Therapy for Rare Disorders Conference.

On-demand webinar

How to maximize roi real world data

Optum experts give a snapshot of commonly encountered pitfalls when using RWD and recommendations to help avoid them in this PMSA webinar.

Article

Reconcile your RWD expectations to maximize your investment

Understand how routine clinical practice impacts information captured in real-world data (RWD).